Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.26 USD
Change Today +0.0195 / 8.11%
Volume 7.5K
As of 10:19 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

26361 Crown Valley Parkway

Suite 150

Mission Viejo, CA 92691

United States

Phone: 949-481-9825


Aeolus Pharmaceuticals, Inc., a biopharmaceutical company, develops a platform of novel compounds in biodefense, oncology and pulmonary disorders. The company’s platform consists of approximately 200 compounds licensed from the University of Colorado (UC) Duke University and National Jewish Health. AEOL 10150 The company’s main compound, AEOL 10150 (10150), is being developed under contract with the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services (HHS), as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Other Product Candidates The company is also developing 10150 as a MCM for exposure to chemical vesicants (e.g., chlorine gas, sulfur mustard gas and phosgene gas) and nerve agents (e.g., sarin gas and soman gas) with grant money from the National Institutes of Healh (NIH) Countermeasures Against Chemical Threats (NIH-CounterACT) program. The company is also developing 10150 for use in combination with radiation therapy for cancer as a treatment to reduce side effects caused by radiation toxicity and improve local tumor control. The company is also developing 10150 for the treatment of lung fibrosis, including idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. This new development program was created based upon the data generated from animal studies in Lung-ARS and chemical gas exposure under the BARDA Contract and NIH grants. Strategy The company’s strategy is to use non-dilutive capital wherever possible to develop its promising platform of broad-spectrum, catalytic antioxidant compounds in important unmet medical indications of clinical and national strategic importance. Research and Development The company’s expenditures related to research and development activities included $6,966,000, as of September 30, 2014. Patents and Proprietary Rights As of December 20, 2013, the company’s catalytic antioxidant small molecule technology base is described in 12 issued United States patents and 5 United States pending patent applications. These patents and patent applications cover soluble manganic porphyrins as antioxidant molecules, as well as targeted compounds obtained by coupling such antioxidant compounds to molecules that bind to specific extracellular elements. The pending U.S. patent applications and issued U.S. patents include composition of matter claims and method claims for several series of compounds. Corresponding international patent applications have been filed, 88 of which have issued, and 1 of which has been allowed to the company, as of December 20, 2013. In 2013, the company filed a provisional patent application with the United States Patent and Trademark Office entitled ‘Synthesis and Formulation of Porphyrin Compounds’. In 2014, a patent application was filed under the Patent Cooperation Treaty (PCT) with the United States Receiving Office (US/RO), thereby preserving the right to seek patent protection in all PCT contracting States. History Aeolus Pharmaceuticals, Inc. was founded in 1994. The company was incorporated in the state of Delaware in 1994.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AOLS:US $0.26 USD +0.0195

AOLS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AOLS.
View Industry Companies

Industry Analysis


Industry Average

Valuation AOLS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AEOLUS PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at